Pulmonx (LUNG)

• Market cap: $271M
• 1 day: -0.73%
• 5 days: 1.19%
• 1 month: -17.73%
• 3 months: 4.60%
• 6 months: -8.33%
• Year to date: 4.60%
• 1 year: -19.86%
• 5 years: -82.65%
• 10 years: -82.65%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Employees: 291

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

60% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 15

12% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 33

5% more funds holding

Funds holding: 112 [Q3] → 118 (+6) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

2.17% less ownership

Funds ownership: 93.15% [Q3] → 90.97% (-2.17%) [Q4]

19% less capital invested

Capital invested by funds: $301M [Q3] → $244M (-$57.6M) [Q4]

100% less call options, than puts

Call options by funds: $4K | Put options by funds: $1.74M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $17 149% upside
• Avg. target: $17 149% upside
• High target: $17 149% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 27% 1-year accuracy 88 / 330 met price target

149% upside $17

Buy Maintained

11 Mar 2025